Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Dose-Finding Study to Evaluate the Safety and Pharmacokinetics (PK) of AMG 706 [motesanib] With Carboplatin/Paclitaxel, AMG 706 With Panitumumab and AMG 706 With Panitumumab and Carboplatin/Paclitaxel in the Treatment of Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC).

Next Previous
Trial Profile

An Open-Label, Dose-Finding Study to Evaluate the Safety and Pharmacokinetics (PK) of AMG 706 [motesanib] With Carboplatin/Paclitaxel, AMG 706 With Panitumumab and AMG 706 With Panitumumab and Carboplatin/Paclitaxel in the Treatment of Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC).

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Mar 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Motesanib (Primary) ; Carboplatin; Paclitaxel; Panitumumab
  • Indications Non-small cell lung cancer
  • Focus Pharmacokinetics
  • Sponsors Amgen

Most Recent Events

  • 21 Mar 2014 The study design has been changed from single group assignment to parallel group assignment and primary endpoint has been changed from safety and pharmacokinetics to pharmacokinetics only as reported by ClinicalTrials.gov record.
  • 21 Mar 2014 The study design has been changed from single group assignment to parallel group assignment and primary endpoint has been changed from safety and pharmacokinetics to pharmacokinetics only as reported by ClinicalTrials.gov record.
  • 25 Aug 2009 Actual end date (Mar 2007) and actual number of patients (51) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top